Fig. 5: Change in CST from baseline through to Week 96 in eyes with early persistent fluid (IRF and/or SRF). | Eye

Fig. 5: Change in CST from baseline through to Week 96 in eyes with early persistent fluid (IRF and/or SRF).

From: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Fig. 5

Analysed using ANOVA model with baseline CST-total categories (<400, > = 400 µm), age categories (<75, > = 75 years) and treatment as fixed effect factors. ANOVA analysis of variance, CST central subfield thickness, LS least squares, SE standard error.

Back to article page